Russia is preparing to introduce an mRNA-based cancer vaccine in early 2025, designed to treat cancer patients rather than prevent the disease. According to a report by state-run media TASS, the vaccine will be distributed free of cost to Russian citizens and will cost the government approximately 300,000 rubles (USD 2,869) per dose.

Andrey Kaprin, head of the Radiology Medical Research Centre of the Ministry of Health, confirmed the vaccine’s launch timeline, while Alexander Gintsburg, Director of the Gamaleya National Research Centre for Epidemiology and Microbiology, explained the advanced technology involved. The vaccine’s development relies on artificial intelligence and neural network computing to create personalised treatments for each patient. "These procedures should take about half an hour to an hour," Gintsburg told TASS.

Unlike traditional vaccines that prevent diseases, this cancer vaccine targets existing tumours, helping the immune system recognise and attack cancer cells. Using genetic material, or RNA, taken from a patient’s tumour, the vaccine teaches the immune system to identify unique cancer proteins and generate antibodies to destroy the cancer cells.

The vaccine is personalised for each patient, a method similar to ongoing research in western nations. However, specific details about the types of cancer the vaccine will target, its efficacy, and distribution logistics remain undisclosed.

Cancer rates in Russia are on the rise, with over 635,000 new cases recorded in 2022. Colon, breast, and lung cancers are the most prevalent. The new vaccine could represent a significant step forward in addressing this growing health crisis.

Global Advances in Cancer Vaccines

Russia’s efforts align with a broader global push toward personalised cancer treatments. In the United States, researchers at the University of Florida have been testing an individualised vaccine for glioblastoma, a highly aggressive brain cancer. In a May study, the vaccine elicited a strong immune response within 48 hours, shifting the tumour environment from "immune cold" to "immune hot," said Elias Sayour, a paediatric oncologist at UF Health.

Meanwhile, the UK is advancing trials of a personalised vaccine for melanoma, the deadliest form of skin cancer. Early results suggest significant improvements in survival rates. Steve Young, a 52-year-old patient involved in the UK trial, expressed optimism: "This is my best chance at stopping the cancer in its tracks."

With personalised cancer vaccines emerging as a global focus, Russia’s upcoming mRNA vaccine could mark an important milestone in the fight against one of the world’s most challenging diseases.